Chugai Seiyaku Kabushiki Kaisha

Genentech, Inc.

Mika Endo

Yasuko Kinoshita

Yuji Sano

Toshihiko Ohtomo

Atsuhiko Kato

Takahiro Ishiguro

Toshiaki Tsunenari

Yumiko Kawai

Yoshinori Narita

Masako Ura

Kenji Adachi

The invention provides compositions and methods for treating cancers. The methods comprising administering a PD-1 axis binding antagonist and an anti-GPC3 antibody. The compositions comprising a pharmaceutical composition for treating cancer which comprises a PD-1 axis binding antagonist and an anti-GPC3 antibody. Also disclosed are a pharmaceutical composition to be used in combination with a PD-1 axis binding antagonist for treating cancer which comprises an anti-GPC3 antibody as the active ingredient; and a pharmaceutical composition to be used in combination with an anti-GPC3 antibody for treating cancer which comprises as the active ingredient a PD-1 axis binding antagonist.

Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies

The present invention provides anticancer agents comprising as an active ingredient a bispecific antibody that comprises a domain comprising a glypican 3-binding antibody variable region, a domain comprising a T cell receptor complex-binding antibody variable region, and common L chains that can enhance the affinity for the two antigens, as well as pharmaceutical compositions comprising the bispecific antibody as an active ingredient, the compositions being for use in combination with other anticancer agents. The bispecific antibodies are novel molecules which are produced with high efficiency and have strong anti-tumor activity as well as safety and excellent pharmacodynamics. The bispecific antibodies can be expected to be applied to various cancers.

Cell injury inducing therapeutic drug for use in cancer therapy

A cancer therapeutic agent comprising a combination of compound A described below, or a pharmaceutically acceptable salt thereof, and compound B described below, or a pharmaceutically acceptable salt thereof:

Combination anticancer agents

Growing community of inventors

Kanagawa, Japan

Mika Endo